

INFORMAL COMMUNICATION**CAMPBELL & FLORES****INFORMAL COMMUNICATION**

Attorneys

Biotechnology Intellectual Property

4370 La Jolla Village Drive, Suite 700
San Diego, California 92122
Telephone: (858) 535-9001
Facsimile: (858) 535-8949
USPTO CUSTOMER NO. 23601

FAX RECEIVED

NOV 01 2002

GROUP 1600**IMPORTANT NOTICE**

The information accompanying this facsimile transmission is intended for the use of the person named below. The information may contain confidential information which may be legally privileged. If you have received this facsimile in error, please notify us immediately by telephone or facsimile to arrange for return of the original documents to us. Thank you.

TO: Examiner: Gabel
Group: 1578

Fax No.: (703) 305-3014

FROM: Pamela M. Guy
Registration No: 51,228

REFERENCE: Serial No. 09/575,061
Filed: May 19, 2000
Entitled: DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE
USING THE PmpC ANTIGEN

DOCKET: P-PM 4097

DATE: October 31, 2002

NO. OF PAGES (Including this page): 3

LIST ALL DOCUMENTS BEING TRANSMITTED:

1. This fax cover sheet (1 page)
2. Proposed Amendment (2 pages)

SPECIAL INSTRUCTIONS:

Please deliver this INFORMAL COMMUNICATION to EXAMINER GABEL.

Please do not enter this transmission as part of the PTO file.

Please contact Pamela M. Guy at (858) 535-9001 if you DO NOT receive all pages.

Original will follow by:

U.S. Mail _____ Express Mail _____ Will Not Follow XX

INFORMAL COMMUNICATION

To: Examiner Gabel
Group Art Unit: 1578
Unofficial Fax Number: (703) 305-3014

From: Pamela Guy
Registration No. 51,228
Phone Number: (858) 535-9001
Fax number: (858) 597-1585

Serial No.: 09/575,061
Filed: May 19, 2000
Our Docket: P-PM 4097

Today's Date: October 31, 2002

Below is a proposed amendment to claim 2 that we believe will address the outstanding indefiniteness rejection of claims 2 to 7. We would like to discuss the proposed claim amendment with you during our telephone interview on Monday, November 4, at 2:00 p.m. EDT. We also would like to discuss the outstanding novelty and obviousness rejections. We appreciate the opportunity to discuss these matters with you.

Proposed Amendment

2. (Three Times Amended) A method of diagnosing Crohn's disease in a subject, comprising the steps of:

- (a) obtaining a sample from a subject suspected of having inflammatory bowel disease;
- (b) contacting the sample with an OmpC antigen, or reactive fragment thereof, under conditions suitable to form a

P-PM 4097
Informal Communication
October 31, 2002
Page 2 of 3

complex of the OmpC antigen, or reactive fragment thereof, and IgA antibody to the OmpC antigen;

(c) contacting said complex with [an] a labeled anti-IgA antibody to form a labeled complex; and

(d) detecting said labeled complex, thereby determining the presence [or absence] of IgA anti-OmpC antibodies,

where the presence of said IgA anti-OmpC antibodies in said subject indicates that said subject has Crohn's disease.

Support for the amendment to claim 2 can be found in the specification, which indicates that an anti-IgA antibody can be a labeled antibody, such as a goat anti-human IgA antibody labeled with alkaline phosphatase (page 37, lines 23-26). The specification describes other labeled secondary antibodies that are labeled with a moiety other than an enzyme, such as an anti-gamma chain specific antibody labeled with fluorescein (page 39, lines 12-16).

Respectfully submitted,

October 31, 2002
Date

Pamela M. Guy
Pamela M. Guy
Registration No. 51,228
Telephone No. (858) 535-9001
Facsimile No. (858) 535-8949

CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
USPTO CUSTOMER NO. 23601